|
|
||||||||
J Thorac Cardiovasc Surg 2009;137:1436-1442
© 2009 The American Association for Thoracic Surgery
Acquired Cardiovascular Disease |
a Department of Anesthesiology, Academic Medical Center AMC, University of Amsterdam, Amsterdam, The Netherlands
b Department of Anesthesiology, University Hospital Duesseldorf, Duesseldorf, Germany
c Department of Thoracic and Cardiovascular Surgery, University Hospital Duesseldorf, Duesseldorf, Germany
d Department of Anesthesiology, Slingeland Ziekenhuis, Doetinchem, The Netherlands
e Department of Anesthesiology, South Tyneside District Hospital, South Shields, United Kingdom
Received for publication January 30, 2008; accepted for publication April 6, 2008. * Address for reprints: Benedikt Preckel, MD, MA, DEAA, Academic Medical Center, University of Amsterdam, Postbus 22660 H1Z-120, 1100 DD Amsterdam, The Netherlands. (Email: b.preckel{at}amc.uva.nl).
Objective: Anesthetic preconditioning may contribute to the cardioprotective effects of sevoflurane in patients having coronary artery bypass surgery. We investigated whether 2 different sevoflurane administration protocols can induce preconditioning in patients having coronary artery bypass.
Methods: Thirty patients were randomly allocated to 1 of 3 groups. All patients received a total intravenous anesthesia with sufentanil (0.3 µg–1 · kg· h–1) and propofol as target controlled infusion (2.5 µg/mL). The control group had no further intervention; 10 minutes prior to establishing the extracorporeal circulation, patients of the sevoflurane-I group received 1 minimum alveolar concentration of sevoflurane for 5 minutes. Patients of the sevoflurane-II group received (2 times) 5 minutes of sevoflurane, interspersed by 5-minute washout 10 minutes prior to extracorporeal circulation. Troponin I was measured as marker of cardiac cellular damage.
Results: Peak levels of troponin I release were observed at 4 hours after cardiopulmonary bypass and were not affected by 1 cycle of sevoflurane administration (controls: 14 ± 3 ng/mL vs sevoflurane-I group, 14 ± 3 ng/mL). Two periods of sevoflurane preconditioning significantly reduced cellular damage compared with controls (peak troponin I level sevoflurane-II group, 7 ± 2 ng/mL).
Conclusion: These data show that sevoflurane-induced preconditioning is reproducible in patients having coronary artery bypass but depends on the preconditioning protocol used.
This article has been cited by other articles:
![]() |
J. Frassdorf, S. De Hert, and W. Schlack Anaesthesia and myocardial ischaemia/reperfusion injury Br. J. Anaesth., July 1, 2009; 103(1): 89 - 98. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |